The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Free Report) in a research note issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock. Calithera Biosciences Price Performance Calithera Biosciences stock opened at $0.05 on Thursday. The company has a fifty day moving average price of $0.18 and […]
Calithera Biosciences (NASDAQ:CALA) Now Covered by Analysts at StockNews com defenseworld.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from defenseworld.net Daily Mail and Mail on Sunday newspapers.
JNCCN study sheds light on a rapid shift in practice evolution by oncologists treating people with colon cancer adjuvantly after primary surgery, following publications from the IDEA collaboration.
StockNews.com assumed coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a report issued on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock. Calithera Biosciences Stock Performance Calithera Biosciences stock opened at $0.05 on Wednesday. The stock’s 50 day moving average price is $0.20 and its 200 day moving […]